Nuformix plc has a complete pre-clinical story for potential licensing partners (VIDEO)

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the twelve months ended 31 March 2023 following the change in the Company’s accounting reference date from 31 March to 30 September.

Executive Director Dr Dan Gooding joins DirectorsTalk Interviews to discuss interim results and an update on its programme NXP002.

Dan talks us through the interim highlights, reminds us of what the NXP002 programme is and what it does, provides us with a summary of the Inflammation results, the Duration of Action results and explains what is next for the Company and NXP002.

Read the full article

Click to view all articles for the EPIC: NFX
Or click to view the full company profile:
Nuformix plc

Nuformix hosting online Q&A session on 13 June 2023

2nd June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT

Nuformix appoints Kreston Reeves as auditor

25th May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves will be

Nuformix continuing to generate value-adding data for its lead programme

22nd May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the twelve months ended 31 March 2023 following the change in the Company’s accounting reference date

Nuformix delighted with NXP002 study results

18th May 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled

Nuformix to raise £70,000 through subscription, to progress NXP002

17th April 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced a subscription to raise gross proceeds of £70,000 through a subscription for 35,000,000 new ordinary shares of 0.1

Nuformix “tranilast at the heart of NXP002” in treating fibrosis (LON:NXF)

12th April 2023

Nuformix’s Dan Gooding discusses what the NXP002 programme is & its purpose, key findings from the results, and what’s next for the company and the programme in this exclusive interview with DirectorsTalk.

Nuformix Dan Gooding says NXP002 meets best case scenario objectives (VIDEO)

29th March 2023

Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP002 study results. Dan is delighted to remind us of what the NXP002 programme is and its purpose, take us through the key

Nuformix updates on the NXP002 programme for treatment of IPF

27th March 2023

Nuformix further evaluating NXP002 combination therapies now underway

15th February 2023

Nuformix updates on NXP004

20th December 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP004 programme, focused on the development of novel, proprietary, cocrystal forms of olaparib,

Nuformix excited by prospects for the remainder of the year

13th December 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 30 September 2022. Operational highlights (including post-period end) · Initial pre-clinical inhalation studies undertaken

Nuformix: Unlocking therapeutic potential in Fibrosis and Oncology

10th November 2022

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.

Nuformix to host online presentation and Q&A session

4th November 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Wednesday 9

Nuformix lead programme introduced to major respiratory players (VIDEO)

23rd September 2022

Nuformix introduces lead programme to major respiratory players

23rd September 2022

Campaign calls for diagnosis of pulmonary fibrosis

15th September 2022

The president of the Portuguese Society of Pulmonology, António Morais, warned that patients should not underestimate symptoms and insisted on the importance of early diagnosis in fibrotic diseases, stressing that it is crucial to stop progression. The campaign

Almost half of cancer deaths are preventable

8th September 2022

Nearly 50% of cancer deaths worldwide are caused by preventable risk factors, such as smoking and drinking alcohol, according to the largest study of the link between cancer burden and risk factors1. Using estimates of cancer cases and

PF awareness means ‘Being here for each other’ in September

3rd September 2022

From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds

No more posts to show

Be sure to check our sister interview main ratings news website